Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab

Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

(2021) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

The presence of SARS CoV2 antibodies in MS patients

(2021) Asya I. Wallach et al.   Multiple Sclerosis and Related Disorders

Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies

(2021) Fabrizio Bonelli et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

(2021) Paul A Kristiansen et al.   LANCET

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

(2021) Amber Salter et al.   JAMA Neurology

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study

(2020) Amit Bar-Or et al.   NEUROLOGY

Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab

(2020) Jeanine Rempe Thornton et al.   Multiple Sclerosis and Related Disorders

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

(2015) L. Kappos et al.   NEUROLOGY

The effect of rituximab on vaccine responses in patients with immune thrombocytopenia

(2013) I. Nazi et al.   BLOOD